Quantcast

Latest linezolid Stories

2011-01-13 00:00:41

As the first step in PolyMedix's US clinical development activities with PMX-30063, it has initiated a Phase 1 clinical trial. (Vocus/PRWEB) January 12, 2011 Last November, PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, received regulatory clearance from the FDA to investigate its new antibiotic candidate, PMX-30063. PMX-30063 was inspired by a key discovery: It is possible to...

2010-12-09 12:08:00

BURLINGTON, Mass., Dec. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic erosion of nine branded agents will significantly constrain growth in the hospital-acquired infections (HAI) drug market through 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. These nine agents -- piperacillin/tazobactam (Pfizer's Zosyn/Tazocin, generics),...

2010-12-02 09:00:00

MALVERN, Pa., Dec. 2, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds surveyed internal medicine physicians cite that the most important factors influencing hospital selection of antibiotics used for inpatient community-acquired pneumonia (CAP) are recommendations from medical society guidelines (e.g. American Thoracic Society guidelines on pneumonia) and recommendations from...

2010-11-02 08:17:00

MALVERN, Pa., Nov. 2, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the leading driver of antibiotic selection in nosocomial pneumonia in the United States is activity against key drug-resistant pathogens. Such pathogens include P. aeruginosa, MRSA, Vancomycin-resistant Staphylococcus aureus and multidrug-resistant Steptococcus pneumonia. "Nosocomial pneumonia is one of...

2010-10-25 12:05:59

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study. For some time, medical practice guidelines have been ambiguous about whether vancomycin or so-called B-lactam antibiotics like penicillin or cephalosporins was the more appropriate therapy for treating patients admitted for...

2010-10-21 06:00:00

NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to...

2010-10-06 08:00:00

MALVERN, Pa., Oct. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences U.S. physician drug selection for treating skin and skin...

2010-09-16 21:15:56

"Anti-pathogenic" drugs block MRSA's production of toxins thus rendering the bacteria harmless, treating the infection and potentially eliminating concern for resistance Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of...

2010-09-13 15:00:00

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as...

2010-09-13 12:05:38

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study. Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA. The study is being presented Sunday at the 50th annual...


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related